Kancera Overview

  • Founded
  • 2010

Founded
  • Status
  • Public

  • Employees
  • 7

Employees
  • Stock Symbol
  • KAN

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $0.53

  • (As of Thursday Closing)

Kancera General Information

Description

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Contact Information

Website
www.kancera.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • Karolinska Institutet Science Park
  • Nanna Svartz Väg 4
  • 171 65 Solna
  • Sweden
+46 08-501 000 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kancera Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.53 $0.50 $0.46 - $1.32 $29.9M 56.1M 85.4K -$0.11

Kancera Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 28,804 24,553 89,039 9,925
Revenue 208 198 584 340
EBITDA (6,099) (5,281) (4,089) (3,782)
Net Income (6,144) (5,320) (4,392) (3,816)
Total Assets 13,264 14,741 10,131 4,744
Total Debt 0 63 161 1,931
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kancera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and
Biotechnology
Solna, Sweden
7 As of 2022

000000

unt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco lab
000000000000000
Menlo Park, CA
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

000000

e et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
0000000000000
Subiaco, Australia
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kancera Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dermira Formerly VC-backed Menlo Park, CA 000 00000 000000&0 00000
0000000 000000 Corporation Subiaco, Australia 0 000.00 000000000 000.00
00000000 000000000 Corporation Melbourne, Australia 00 000000&0
000000 00000000000 Venture Capital-Backed Amsterdam, Netherlands 00.000 00000000000 00.000
To view Kancera’s complete competitors history, request access »

Kancera Patents

Kancera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3105566-A1 Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 Pending 06-Jul-2018 0000000000
US-20210292349-A1 Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 Pending 06-Jul-2018 0000000000
JP-2021530474-A 7-amino-5-thio-thiazolo [4,5-d] pyrimidine phosphate and phosphonate derivatives and their use in therapeutic conditions associated with elevated levels of cx3cr1 and / or cx3cl1 Pending 06-Jul-2018 0000000000
AU-2019297572-A1 Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo(4,5-d)pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 Pending 06-Jul-2018 0000000000
GB-201811169-D0 New compounds Ceased 06-Jul-2018 C07F9/6561
To view Kancera’s complete patent history, request access »

Kancera Executive Team (2)

Name Title Board Seat Contact Info
Thomas Olin Ph.D Founder, Chief Executive Officer & Board Member
Martin Norin Ph.D Chief Operating Officer
To view Kancera’s complete executive team members history, request access »

Kancera Board Members (1)

Name Representing Role Since
000000 0000 00.0 Kancera Founder, Chief Executive Officer & Board Member 000 0000
To view Kancera’s complete board members history, request access »

Kancera Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kancera Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 17-Feb-2011 0000000000 00000 Drug Discovery 000000 00
To view Kancera’s complete acquisitions history, request access »